Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: SAT1

Summary for SAT1

Gene information	Gene symbol	SAT1
	Ensembl ID	ENSG00000130066
	Entrez ID	6303
	Gene name	spermidine/spermine N1-acetyltransferase 1
	Synonyms	SAT\|SSAT
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: SAT1

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE131984_Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	NA	Malignant cells	-0.388078	4.09e-07
GSE163836	FCIBC02 cell line	Cell line	Breast cancer	Inflammatory breast cancer	Chemotherapy	paclitaxel	NA	Malignant cells	0.285708	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	-0.426851	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.609231	2.06e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD4+ T cells	0.469967	6.46e-16
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.441163	7.91e-41
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Plasma cells	0.387411	4.68e-08
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	0.387978	2.61e-05
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Mono/Macro	-0.808967	3.00e-02
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.68392	2.79e-36
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.298666	7.55e-07
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.391644	3.82e-13
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.505218	1.12e-14
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.476459	2.96e-17
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.774099	0.00e+00
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.37205	3.70e-17
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Malignant cells	-0.91551	1.21e-02
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-1.3045	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-1.47162	0.00e+00
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.677111	1.22e-16
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.889449	4.70e-03
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	1.15804	2.87e-40
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.572085	5.48e-07
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	CD4+ T cells	-0.271959	1.48e-32
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	NK cells	-0.328935	1.07e-41
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Neutrophils	0.794158	1.32e-26
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Malignant cells	0.345017	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Mono/Macro	0.629799	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	1.10662	1.84e-20
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Mono/Macro	0.598352	2.68e-37
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	1.11546	8.95e-28
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	2.44926	0.00e+00
GSE168668	LNCaP cell line	Cell line	Prostate cancer	Prostate cancer	Targeted therapy	enzalutamide	NA	Malignant cells	-1.70417	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	0.631467	4.89e-17
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.64189	8.79e-04
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.972059	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-1.7599	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.390732	1.26e-41
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	0.923853	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.80266	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	Malignant cells	0.3044	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	pre	CD8+ T cells	-0.449589	1.55e-06
GSE152469	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	NA	Malignant cells	0.376373	0.00e+00
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	0.293886	7.96e-07
GSE131984_Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	palbociclib	NA	Malignant cells	0.313855	6.14e-04
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	0.630889	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.378109	5.80e-41
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Mono/Macro	-0.281767	2.42e-07
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	1.15539	0.00e+00
GSE175716	PDX	Tumor tissue	Liver cancer	Advanced hepatocellular carcinoma	Targeted therapy	sorafenib	NA	Malignant cells	-0.912928	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	0.371741	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	0.939066	0.00e+00

Top

Expression of SAT1 in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to SAT1

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating SAT1

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
SAT1	hsa-miR-493-5p	97.9641	NM_002970
SAT1	hsa-miR-607	97.6521	NM_002970
SAT1	hsa-miR-4670-3p	92.5345	NM_002970
SAT1	hsa-let-7c-3p	88.8437	NM_002970
SAT1	hsa-let-7g-3p	88.8437	NM_002970
SAT1	hsa-let-7a-2-3p	88.8437	NM_002970
SAT1	hsa-miR-551b-5p	88.7764	NM_002970
SAT1	hsa-miR-3177-5p	86.1529	NM_002970

Page: 1

Top

Motifs and transcription factors (TFs) regulating SAT1

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
SAT1	hocomoco__TYY2_HUMAN.H11MO.0.D	YY2 (directAnnotation).
SAT1	jaspar__MA0604.1	ATF1 (inferredBy_Orthology).
SAT1	metacluster_141.2	E2F2; E2F3 (directAnnotation).
SAT1	metacluster_168.3	NR4A1 (directAnnotation).
SAT1	metacluster_127.3	FOXO1; FOXO3; FOXO4 (directAnnotation).
SAT1	transfac_pro__M06388	ZNF677 (directAnnotation).
SAT1	taipale_tf_pairs__GCM1_CEBPB_ATRSGGGNNNNTTRCGYAAN_CAP_repr	CEBPB; GCM1 (directAnnotation).
SAT1	metacluster_22.27	NFE2L2 (inferredBy_Orthology).
SAT1	transfac_pro__M04746	E2F1 (directAnnotation).
SAT1	transfac_pro__M02082	ISL2 (directAnnotation).
SAT1	metacluster_111.6	GMEB1; GMEB2 (directAnnotation).
SAT1	nitta__CG18619_TCGAAG20NGA_KH_RTGACGTCAT_m1_c3u	CREBL2 (inferredBy_Orthology).
SAT1	transfac_public__M00040	ATF2 (directAnnotation).
SAT1	metacluster_172.6	CHD2; E2F1 (directAnnotation).
SAT1	taipale_tf_pairs__TEAD4_FIGLA_RATTCCNNNNNNNNNNCASSTGN_CAP_repr	FIGLA; TEAD4 (directAnnotation).
SAT1	transfac_pro__M05935	ZNF382 (directAnnotation).
SAT1	transfac_pro__M05350	ZNF146 (directAnnotation).
SAT1	transfac_pro__M06435	ZNF429 (directAnnotation).
SAT1	transfac_public__M00039	CREB1 (directAnnotation).
SAT1	transfac_pro__M05538	ZNF536 (inferredBy_Orthology).
SAT1	metacluster_2.7	IRF1; IRF1; IRF2; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF7; IRF8; IRF8; IRF9; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; PRDM1; STAT1; STAT1; STAT2 (directAnnotation). PRDM1; PRDM1; PRDM1 (inferredBy_Orthology).
SAT1	tfdimers__MD00007	E2F1; IRF8 (directAnnotation).
SAT1	metacluster_172.22	E4F1 (inferredBy_Orthology).
SAT1	transfac_pro__M04955	ZBTB33 (directAnnotation).
SAT1	hocomoco__GMEB2_HUMAN.H11MO.0.D	GMEB2 (directAnnotation).
SAT1	metacluster_44.7	NKX3-2 (directAnnotation).
SAT1	tfdimers__MD00335	FOXP3; NKX2-1 (directAnnotation).
SAT1	metacluster_52.10	GTF3C2; ZNF436 (directAnnotation).
SAT1	dbtfbs__ZNF26_HEK293_ENCSR028EGI_merged_N1	ZNF26 (directAnnotation).
SAT1	transfac_pro__M06636	ZNF599 (directAnnotation).
SAT1	kznf__ZNF197_Imbeault2017_OM_RCADE	ZNF197 (directAnnotation).
SAT1	transfac_pro__M06949	EVX2 (directAnnotation).
SAT1	taipale_tf_pairs__TEAD4_SPDEF_RGWATSCGGATGNNNNTCCKNNN_CAP_repr	SPDEF; TEAD4 (directAnnotation).
SAT1	cisbp__M00311	PITX2 (directAnnotation).
SAT1	tfdimers__MD00312	NANOG (directAnnotation).
SAT1	tfdimers__MD00425	ELF5; SMAD4 (directAnnotation).
SAT1	transfac_pro__M06218	ZNF169 (directAnnotation).
SAT1	kznf__ZNF649_Imbeault2017_OM_RCADE	ZNF649 (directAnnotation).
SAT1	tfdimers__MD00175	EP300; GTF2IRD1 (directAnnotation).
SAT1	hocomoco__DPRX_HUMAN.H11MO.0.D	DPRX (directAnnotation).
SAT1	transfac_pro__M06484	ZNF683 (directAnnotation).
SAT1	metacluster_135.11	NR2C2 (directAnnotation).
SAT1	metacluster_198.3	ZFP64 (directAnnotation).
SAT1	jaspar__MA0185.1	DEAF1 (inferredBy_Orthology).
SAT1	metacluster_91.4	GZF1; HSFY2 (directAnnotation).
SAT1	metacluster_22.21	NFE2L2 (inferredBy_Orthology).
SAT1	transfac_pro__M06643	ZNF583 (directAnnotation).
SAT1	transfac_pro__M01069	GZF1 (directAnnotation).
SAT1	metacluster_29.6	ZNF436 (directAnnotation).
SAT1	tfdimers__MD00281	CDX2; HNF4A; HNF4G; NR2F1; NR2F2 (directAnnotation).

Page: 1 2

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
SAT1	"N-ethyl-N-[3-(propylamino)propyl]propane-1,3-diamine"	DB04633	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."